Skip to content

Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis

Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05902455
Enrollment
40
Registered
2023-06-15
Start date
2021-05-25
Completion date
2025-06-30
Last updated
2023-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Squamous Cell Carcinoma

Keywords

Oral squamous cell carcinoma, Differential mobility spectrometry (DMS), Automatic tissue analysis (ATAS)

Brief summary

The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an electrosurgical instrument. Patients recruited in the trial receive standard-of-care oral squamous cell carcinoma tumor excision surgery.

Detailed description

Oral squamous cell carcinoma is the sixth common carcinoma and the cause of 1-2% of cancer related deaths in the world. The incidence of oral squamous cell carcinoma was 255 cases in Finland and 742 270 cases worldwide in year 2015. The number of cases per year has been increasing. The approximate age of tumor occurrence is usually between 60 - 70 years. The 5-year survival rate of all diagnosed oral squamous cell carcinoma cases in Finland during the years between 2014 and 2016 was 67% for women and 61% for men. Early diagnostics is relevant, since oral squamous cell carcinoma tumors have a tendency to grow rapidly and metastasize early to regional lymphnodes and later on to lungs, liver and bones. Typical locations of the tumor are tongue, gums and sole of mouth. The primary treatment option for oral squamous cell carcinoma is surgical removal of the tumor with 0,5 - 1cm healthy tissue margin. The aim of the operation is to remove the tumor entirely so that the healthy tissue margins are as sparing as possible and that the functional and cosmetic outcomes are as satisfactory as possible. Sufficient healthy tissue margin is one of the most important prognostic factors. Nevertheless, there is only little evidence based knowledge of sufficient healthy tissue margins. Differential mobility spectrometry (DMS) based application called automatic tissue analysis (ATAS) can be utilized to identify tumor cells from healthy tissue. Tissue identification is done by analyzing tissue smoke that is generated by the use of an electrosurgical instrument called diathermy. The objective of the trial is to test whether it is possible to identify oral squamous cell carcinoma tissue from normal oral mucosa by using ATAS. A 4mm punch biopsy of an oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa will be collected from 30 - 40 patients undergoing oral tumor excision. The biopsies will be examined in the research laboratory with ATAS to test tissue recognition.

Interventions

PROCEDUREPunch biopsy

Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.

Sponsors

Olfactomics Oy
CollaboratorUNKNOWN
Tampere University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Biopsy diagnosed oral squamous cell carcinoma. * Tumor diameter of 2 cm or larger. * Operable patient that is willing to participate in the trial.

Exclusion criteria

* Tumor diameter less than 2 cm. * Patient that is unwilling to take part in the trial. * Patient that is not able to understand given information concerning the trial or to give concent to take part in the trial.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity of normal and cancerous tissue identification by differential mobility spectrometryThrough study completion, an average of 1 yearThe ATAS device records a molecular spectrum of the surgical smoke generated when the collected tissue samples are processed with an electrosurgical instrument in the research laboratory. The primary outcome of the study is to test the ability of the device to correctly distinguish cancerous tissue from normal tissue based on predicted differences in the spectrum.

Secondary

MeasureTime frameDescription
The influence of oral squamous cell carcinoma tumor thickness and infiltration depth on the resolutionThrough study completion, an average of 1 yearThe overall thickness of the tumor and the infiltration depth of the tumor, both presented in millimetres, can have an effect on the resolution of cancerous tissue.

Countries

Finland

Contacts

Primary ContactAnni Salminen, M.D.
anni.h.salminen@tuni.fi+358503467184
Backup ContactAntti Roine, M.D, Ph.D.
antti.roine@olfactomics.fi+358408410698

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026